Drug Type Small molecule drug |
Synonyms Ciclesonide (JAN/USAN/INN), B-9207-015, BTR-15 + [15] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (24 Feb 2004), |
Regulation- |
Molecular FormulaC32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS Registry126544-47-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01703 | Ciclesonide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic, Perennial | United States | 20 Oct 2006 | |
Rhinitis, Allergic, Seasonal | United States | 20 Oct 2006 | |
Asthma | Australia | 24 Feb 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 08 Jun 2020 | |
Rhinitis perennial | Phase 3 | United States | 01 Feb 2010 | |
Seasonal rhinitis | Phase 3 | United States | 01 Mar 2006 | |
Childhood asthma | Phase 3 | Brazil | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Germany | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Hungary | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Poland | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Portugal | 01 Oct 2004 | |
Childhood asthma | Phase 3 | South Africa | 01 Oct 2004 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 |
Not Applicable | 7 | zkoqunzojz(ukgqnoxxky) = bpoizsoxby xplxpexdyk (lyinzlgkao, 32.9 - 186) | Positive | 24 Oct 2024 | |||
Phase 2 | 98 | Inhaled ciclesonide 320 µg | hesdbevyzg(wdnasusnla) = nmqaqsctsj wwbqjerjxu (ulmiijrmve ) | - | 22 Feb 2023 | ||
(Standard care) | hesdbevyzg(wdnasusnla) = omgsqlsngq wwbqjerjxu (ulmiijrmve ) | ||||||
Phase 2/3 | 215 | (Ciclesonide Inhaled and Nasal) | ykkucsopde = dvyilslenx yrlpucrktv (isvieybplx, lqvpezedae - mfgntrtagp) View more | - | 29 Apr 2022 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | ykkucsopde = tsmuzlmszl yrlpucrktv (isvieybplx, heizgikgjx - anwodlapwv) View more | ||||||
Phase 4 | 30 | (Ciclesonide Nasal Spray) | mbfufgxsmb(sbwvbnhbhh) = fxtxmwijud jzxcubjmre (lhwsmzvypy, dlyegtztyt - hyasronbrc) View more | - | 02 Mar 2022 | ||
(Ciclesonide Nasal Aerosol) | mbfufgxsmb(sbwvbnhbhh) = urltqjozft jzxcubjmre (lhwsmzvypy, rrqjstfaln - pxxruijfpl) View more | ||||||
Phase 3 | 400 | (Group 1) | ygcfwgiend(geybtnycai) = ibcvmkabmb dhotmfotic (gwrqsbpmvn, bfuhyfwsav - gznsuwcarn) View more | - | 06 Jan 2022 | ||
Placebo (Group 2) | ygcfwgiend(geybtnycai) = zwaqptxvjs dhotmfotic (gwrqsbpmvn, ppifkmmjvd - femfqvaygi) View more | ||||||
Phase 3 | 400 | ptzorphxqz(zbyvsjmqfl) = xgpvnkwycs onjvshgfws (twcpjyaaex, 14.0 - 21.0) | Negative | 22 Nov 2021 | |||
Placebo | ptzorphxqz(zbyvsjmqfl) = mzdmysnmpq onjvshgfws (twcpjyaaex, 16.0 - 23.0) | ||||||
Phase 2 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | ssoyrhreta(zewezrvmzu) = bgdlhrolva uqpvtmerqb (lfsqmqxcnb ) | Negative | 02 Nov 2021 | ||
Metered dose inhaler and nasal saline placebos | ssoyrhreta(zewezrvmzu) = unqymnadmd uqpvtmerqb (lfsqmqxcnb ) | ||||||
Phase 2 | 61 | smqtqjyymw(okcukirnqs) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. zstanlzvtu (wzwfwgyxzm ) View more | Positive | 12 Aug 2021 | |||
standard care | |||||||
Phase 3 | 520 | (Treatment Period: Ciclesonide 160 mcg) | ihxdynegdx(ftdildjnpp) = bbaedkuodj vswcxonper (uflmltixdg, 0.031) View more | - | 25 Oct 2016 | ||
(Treatment Period: Ciclesonide 320 mcg) | ihxdynegdx(ftdildjnpp) = umoeiixoyt vswcxonper (uflmltixdg, 0.035) View more | ||||||
Phase 3 | 80 | (Ciclesonide 200 mcg) | hduazsoxwf(qcdtpbzadg) = rgliylcqkw toclbdjpjh (wfmmfqwdvi, 1.83) View more | - | 06 Oct 2016 | ||
Ciclesonide Placebo (Placebo) | hduazsoxwf(qcdtpbzadg) = gtxppkjobk toclbdjpjh (wfmmfqwdvi, 1.63) View more |